Fast forwarding to the near future and based on the recent past, sequencing instrument companies will continue to develop more user-friendly and cheaper technology, focused on the benchtop and clinical markets. On a worldwide basis, research, discovery, and development applications comprise the two largest sequencing markets. By far the largest market opportunity, though, is in personal genomics and clinical diagnostics. These segments are expected to reach $541 million by 2015 from $15.5 million in 2010. Recent advancements in the field of next-generation sequencing have resulted in the advent of so-called personal genome machines. Companies aiming at the clinical space will need to gain regulatory approval for their use in clinical laboratory diagnostics. What do you think this year holds for sequencing technologies in the clinical space?

Poll Question:
Do you think personal sequencing platforms will enter the clinical diagnostic arena this year?




Previous articleBiogen Idec Pays Isis $29M for Option to Early-Clinical SMA Antisense Therapy
Next articleApogenix Raises €7.5M to Progress Glioblastoma Drug Through Phase II